直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
Finnegan
Melanie M. Magdun
Associate
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4156
melanie.magdun@finnegan.com melanie.magdun@finnegan.com

Melanie M. Magdun

Associate

  • +1 202 408 4156 +1 202 408 4156
  • melanie.magdun@finnegan.com melanie.magdun@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard

Melanie Magdun focuses on patent litigation, prosecution, and post-grant proceedings related to a wide array of areas in the chemical field, including chemicals, pharmaceuticals, medical devices, and energy technologies.

While in law school, Melanie worked as a summer associate at Finnegan, assisting in litigation matters before federal district courts, the Court of Appeals for the Federal Circuit, and the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She served as a Milt Stewart Fellow for a prominent intellectual property firm in Vietnam and participated in the Intellectual Property Clinic at Indiana University, drafting patent applications and filing office action responses. She also worked as a research assistant, conducting research on current changes in trademark and patent law, with an emphasis on design patents and plant patents.

Melanie is committed to her pro bono practice and represents honorably discharged veterans before the U.S. Court of Appeals for Veterans Claims.

Et Cetera

  • Executive notes and comments editor, Indiana Journal of Law and Social Equality, 2020-2021.

Experience

Bial - Portela & CA S.A. v. Torrent Pharmaceuticals Ltd.

Representing Bial in district court Hatch-Waxman litigation involving the anti-epileptic drug Aptiom®.

1:18-cv-00304; 1:18-cv-00382; 1:18-cv-00341; 1:18-cv-00342; 1:18-cv-00336; 1:18-cv-00312; 1:18-cv-00775; 1:18-cv-00279, D. Del., Judges Connolly, Thynge

Insights

At the PTAB Blog

Claim Components Without Amount or Function Limitations Anticipated by Bare Disclosure Claim Components Without Amount or Function Limitations Anticipated by Bare Disclosure

May 9, 2022

Prosecution First Blog

Relative Terms Sufficient for Reasonable Certainty Relative Terms Sufficient for Reasonable Certainty

April 22, 2022

Prosecution First Blog

Inventorship Fight Club: Federal Circuit Finds Insufficient Evidence for Joint Inventorship Inventorship Fight Club: Federal Circuit Finds Insufficient Evidence for Joint Inventorship

January 7, 2022

At the PTAB Blog

The Virtues of Claiming Precisely What the FDA Approved! The Virtues of Claiming Precisely What the FDA Approved!

January 3, 2022

At the PTAB Blog

A Whole Lot of “Cobbl[e]”-ty Gook After Wertheim A Whole Lot of “Cobbl[e]”-ty Gook After Wertheim

December 21, 2021

At the PTAB Blog

Moderna’s Appeal of PTAB Decision Dismissed for Lack of Standing Moderna’s Appeal of PTAB Decision Dismissed for Lack of Standing

December 20, 2021

Admissions and Education

Admissions

  • District of Columbia
  • U.S. Patent and Trademark Office

Education

Indiana University Maurer School of Law
J.D., cum laude, 2021
Vanderbilt University
B.E., Chemical Engineering, 2018

Melanie's Practices

Patent Litigation
Patent Office Examinations
Prosecution
Post-Grant Proceedings
Trade Secrets

Melanie's Industries

Blockchain, NFTs, and Other Digital Assets
Chemicals, Industrials, and Materials
Chemical
Manufacturing
Consumer Goods and Services
Consumer Products
Energy
Clean Energy and Renewables
Life Sciences
Medical Device and Diagnostics

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2022 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP